Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Omeros Corporation

< Previous 1 2 Next >
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Second Quarter 2024 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports First Quarter 2024 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Third Quarter 2023 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Second Quarter 2023 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports First Quarter 2023 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
From Omeros Corporation
Via Business Wire
Tickers OMER
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.